Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Eli Lilly Stock Popped Today

TheMotleyFool

0 0

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases.

In one, Lilly announced plans to acquire the farnesoid X receptor (FXR) program of clinical-stage biotech (NASDAQ: ONVO), including its lead asset, FXR314, a drug that aims to treat ulcerative colitis and metabolic dysfunction-associated steatohepatitis (MASH).

In an unrelated announcement, Lilly said it has cut the price for 2.5-milligram and 5-mg vial doses of its Zepbound (tirzepatide) GLP-1 weight loss drug. Lilly also launched larger-dose vials of 7.5 mg and 10 mg, respectively, each costing $499 per one-month supply.

Source Fool.com